MAGNESIUM SULFATE | N020309 | HOSPIRA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Lachman Consultant Services, Inc. FDA-2024-P-0667 Lachman Consultant Services, Inc. filed this suitability petition on behalf of a client requesting that the FDA declare Magnesium Sulfate in Water for Injection, 3 g/100 mL (30 mg/mL) suitable for submission in an ANDA under Section 505(j)(2)(C) of the FD&C Act, with the reference listed drug being | Suitability | 2024-02-06 | Open | Lachman Consultant Services |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.